Lindus key facts
as of Oct 2026- Developer of a clinical research platform designed to manage and execute clinical trials with improved speed and oversight.
- Lindus is valued at approximately $286.4M as of Oct 2026 (last reported valuation).
- It has raised $81.3M; the latest was Early Stage VC ($55.2M) in Jan 2025.
- Notable investors include Innovate UK, Tech Nation Group, Seedcamp, Salica Investments, Balderton Capital — 29 tracked in total.
- Status: Privately Held (backing).
Lindus's last reported valuation, Jan 2025. Nothing priced has surfaced since.
- ·The complete investor list: 29 names
- ·Watch Lindus: the Monday email on marks, rounds and moves
Lindus funding rounds
No funding rounds for Lindus are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Lindus
29+Membership and data by Private Market View
Lindus valuation
Lindus's last reported valuation was $286 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.
Lindus investors
29 investors are on record for Lindus, including Innovate UK, Tech Nation Group, Seedcamp and Salica Investments. By type, the record holds 6 venture capital firms and 1 angel investor.
About Lindus
Developer of a clinical research platform designed to manage and execute clinical trials with improved speed and oversight. The company offers integrated trial operations, centralized enrollment infrastructure, flexible site models, and an AI-native operating system, enabling biotechnology and pharmaceutical organizations to conduct studies efficiently and meet timelines.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2021
- Employees
- 99
- Website
- lindushealth.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.